Ankylosing Spondylitis Drugs Market Growth 2022-2028: The Rise in The Incidence Rate of Ankylosing Spondylitis, The Elevating Focus On R&D Activities

The global Ankylosing Spondylitis Drugs Market is forecast to reach USD 8,413.0 Million by 2028, according to a new report by Reports and Data.

The global Ankylosing Spondylitis Drugs Market is forecast to reach USD 8,413.0 Million by 2028, according to a new report by Reports and Data. Ankylosing spondylitis (AS) can be described as a type of arthritis, which is not commonly observed among the patients of arthritis. The condition results in stiffness and pain in the spine. It is a chronic condition, which usually begins with the lower back. However, it can also spread up the neck or damage other joints in the body. In severe condition, it can result in hunching the spine.

Access Free sample PDF Copy of the Report @ https://www.reportsanddata.com/sample-enquiry-form/2427

Though the condition is not curable, medication, along with exercise, can help in coping up with the condition. AS often starts in the sacroiliac joints; it is the place where the spine connects to the pelvis. The signs associated with the condition usually appear prior to the age of 45. Some of the common symptoms associated with the condition are mild aches in the low back or buttocks, which are inconsistent. The pain related to the condition usually worsens in the morning or after sitting for a prolonged period. The main focus of the medication prescribed to a patient of AS is managing the pain and controlling the symptoms. The first line of treatment for AS is nonsteroidal anti-inflammatory drugs (NSAIDs). Some of these medications are sold over the counter; others require prescription. Some of the mentionable NSAIDs are Celecoxib, Diclofenac, and Meloxicam, among others. It works by calming the pain by preventing the body from developing prostaglandins, i.e., the inflammation-causing chemicals. In severe conditions, stronger medications like biologics are prescribed.

Companies considered and profiled in this market study:

Merck & Co., Boehringer Ingelheim, UCB, Amgen, Janssen Biotech, Inc., Johnson & Johnson, Abbvie, Hetero, Zydus Cadila and Izana Bioscience.

Get In detailed Research Study @ https://www.reportsanddata.com/report-detail/ankylosing-spondylitis-drugs-market

Further key findings from the report suggest

  • The Ankylosing Spondylitis Drugs market held a market value of USD 5.60 Billion in the year 2018 that is forecasted to grow at a rate of 5.1% during the forecast period.
  • In context to Drug Type, the Nonsteroidal Anti-Inflammatory Drugs segment generated the highest revenue of USD 2.58 Billion in 2018, with a CAGR of 5.3% during the forecast period. Its effectiveness in minimizing inflammation, which is a major impact of the diseases and the main goal of the care services, results in a high demand for Nonsteroidal Anti-Inflammatory Drugs among care providers that contributes to the revenue generated by this segment.
  • In context to Route of Administration, the Parenteral segment is projected to witness a faster growth rate of 4.3% during the forecast period, which is expected to occupy 35.0% of the market by 2027. The growth rate witnessed by the segment is attributed to the presence of strong pipeline products and continuous development in biologics that are needed to be administered in this way. The fact that medications, when administered in the form of injectable, works the specific problem area and given prompt result, have resulted in its growing popularity care providers.
  • In context to Distribution Channel, the Online Pharmacy segment is projected to witness the fastest growth rate of 5.8% during the forecast period, which is expected to occupy 26.5% by 2027. The growth of online medicine shops, rising trend of online purchase of medicine due to benefits like comfort, convenience, and various offers in these shops contributes to the growth rate witnessed by this segment.
  • In regards to Application, the Adults segment generated a higher revenue of USD 4.09 Billion in 2018, with a CAGR of 5.5% during the forecast period. The fact that the signs associated with the condition usually initiates in adulthood and appears prior to the age of 45 results in higher application of these medications among adults.
  • In regards to the region, Asia Pacific is projected to witness the fastest growth rate of 5.7% during the forecast, which is expected to hold 0% of the market by 2027. The growth rate witnessed by the region is resultant of the expansion of the health care sector, and increasing focus on R&D activities, which is supporting the market growth in this region.

Download Summary @ https://www.reportsanddata.com/download-summary-form/2427

For the purpose of this report, Reports and Data have segmented the global Ankylosing Spondylitis Drugs market, according to Drug Type, Route of Administration, Distribution Channel, Application and Region:

Drug Type Outlook (Revenue, USD Billion; 2018-2028)

  • Nonsteroidal Anti-Inflammatory Drugs
  • Anti-Inflammatory Drugs
  • Immunosuppressive Drugs
  • TNF blockers
  • JAK Inhibitors
  • Steroids
  • Biologics
  • Others

Route of Administration Outlook (Revenue, USD Billion; 2018-2028)

  • Parenteral
  • Oral

Distribution Channel Outlook (Revenue, USD Billion; 2018-2028)

  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Application Outlook (Revenue, USD Billion; 2018-2028)

  • Adults
  • Juveniles

Regional Outlook (Revenue, USD Billion; 2018-2028)

  • North America
    • U.S
  • Europe
    • U.K
    • France
  • Asia Pacific
    • China
    • India
    • Japan
  • MEA
  • Latin America
    • Brazil

Ask for Customize Research Report @ https://www.reportsanddata.com/request-customization-form/2427

This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges, that will determine the market’s future growth.

Explore Latest Trending Research Reports By Reports and Data’s:

Dengue Testing Market Size, Share And Industry Analysis By Product Type (ELISA–Based Test, RT-PCR-Based Tests, Dengue lgG/lgM Rapid Test, and Others), By End-Use (Hospitals, Diagnostic Centers, and Others), and Region Forecast To 2028

Growth Hormone Drug Market , By Application Type (Growth Hormone Deficiency, Prader-Willi Syndrome, Turner Syndrome, Small for Gestational Age, and Others), By Route of Administration (Intravenous, Intramuscular, Subcutaneous, and Oral), By End-use (Hospital Pharmacy, Retail Pharmacy, Clinics, and Online Pharmacy), and By Region Forecast to 2028

Nasal Antihistamines Market Size, Share And Industry Analysis By Dosage Form Type (Sprays, Drops, and Gels), By Age Group (Infants, Pediatric, and Geriatric), By End Use (Hospitals, Clinics, Pharmacy, and Homecare Setting), and Region Forecast To 2028

Antipsychotics Market Research, Analysis, and Forecast, 2021-2028

Micro Forceps Market Research, Analysis, and Forecast, 2021-2028

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs